• Markets
    • icon
  • Companies
PIQ · ASX

Proteomics International Laboratories Ltd. (ASX:PIQ)

AU$0.9

 -0.02 (-2.174%)
ASX:Live
04/12/2023 04:10:48 PM
HALO Ords HALO Consensus Value GROWTH AUS Fakey Shakey - Short (Realtime) Fakey Shakey - Short +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PIQ Overview

PIQ Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About PIQ

Website

N/A

Telephone

61.8.9389.1992

Address

QQ Block, Nedlands 6 Verdun Street QEII Medical Centre Perth, Western Australia (WA) 6009

Description

Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company was founded by Richard Lipscombe and Bill Parker in 2001 and is headquartered in Perth, Australia.

PIQ Price Chart

Key Stats

Market Cap

AU$109.49M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.61 - 1.18

Trade Value (12mth)

AU$19,589.00

1 week

4.55%

1 month

5.75%

YTD

-7.54%

1 year

6.98%

All time high

1.48

Key Fundamentals

EPS 3 yr Growth

165.000%

EBITDA Margin

%

Operating Cashflow

-$6m

Free Cash Flow Return

-96.40%

ROIC

-104.60%

Interest Coverage

N/A

Quick Ratio

7.60

Other Data

Shares on Issue (Fully Dilluted)

118m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PIQ Announcements

Latest Announcements

Date Announcements

31 October 22

September 2022 Quarterly Activities Report and Appendix 4C

×

September 2022 Quarterly Activities Report and Appendix 4C

31 January 23

Letter of intent with Sonic Healthcare USA extended

×

Letter of intent with Sonic Healthcare USA extended

31 January 23

December 2022 Quarterly Activities Report and Appendix 4C

×

December 2022 Quarterly Activities Report and Appendix 4C

31 August 20

Annual Report to shareholders

×

Annual Report to shareholders

31 August 17

Annual Report to shareholders

×

Annual Report to shareholders

30 September 15

Annual Report to shareholders

×

Annual Report to shareholders

30 October 23

Investor Presentation

×

Investor Presentation

30 June 22

Endometriosis clinical validation study readout positive

×

Endometriosis clinical validation study readout positive

30 August 22

Corporate Governance Statement and Appendix 4G

×

Corporate Governance Statement and Appendix 4G

30 August 22

Preliminary Final Report

×

Preliminary Final Report

30 August 22

Annual Report to shareholders

×

Annual Report to shareholders

30 August 21

Annual Report to shareholders

×

Annual Report to shareholders

30 August 19

Annual Report to shareholders

×

Annual Report to shareholders

29 September 23

PromarkerD US reimbursement price & Aus regulatory decision

×

PromarkerD US reimbursement price & Aus regulatory decision

29 September 23

Reinstatement to Quotation

×

Reinstatement to Quotation

29 September 23

Proteomics International Webinar and Q&A

×

Proteomics International Webinar and Q&A

29 August 22

OxiDx launched to maximise oxidative stress technology

×

OxiDx launched to maximise oxidative stress technology

28 November 19

Proteomics AGM Presentation

×

Proteomics AGM Presentation

28 November 17

Proteomics AGM Presentation

×

Proteomics AGM Presentation

28 July 22

June 2022 Quarterly Activities Report and Appendix 4C

×

June 2022 Quarterly Activities Report and Appendix 4C

28 August 18

Annual Report to shareholders

×

Annual Report to shareholders

28 April 22

March 2022 Quarterly Activities Report and Appendix 4C

×

March 2022 Quarterly Activities Report and Appendix 4C

27 September 22

New Oesophageal Cancer Diagnostic shows strong performance

×

New Oesophageal Cancer Diagnostic shows strong performance

27 October 20

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

27 October 17

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

27 March 23

Application for quotation of securities - PIQ

×

Application for quotation of securities - PIQ

27 March 23

Exercise of Options

×

Exercise of Options

27 January 23

Application for quotation of securities - PIQ

×

Application for quotation of securities - PIQ

PIQ Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.05 -0.05 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.05 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.5 -67.6 -12.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.04 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.03 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.1 -85.9 -15.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.6 -3.7 -6.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.07 0.03 0.07 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.07 0.03 0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock 50.6 -55.6 115.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 102 106 116 Lock Lock Lock
Basic m Lock Lock Lock Lock 102 106 116 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -7.9 13.6 -51.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -3 -5 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.5 -105.4 -35.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -198.5 -358.9 -993.2 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 299 459 1,093 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -6 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -35.6 -56.7 -22.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -305.2 -421.1 -1,053.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -7 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -32.0 -52.9 -22.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -333.7 -449.1 -1,125.9 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -4 -7 -8 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -5 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.0 -73.9 -24.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -218.2 -333.9 -845.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -4 -6 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 6 0 11 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -4 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.5 -52.0 -88.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.8 -2.5 -9.5 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 6 2 6 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 9 5 10 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -6 -2 -6 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 8 3 8 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 8 3 8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 68.8 -55.4 147.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -33.3 -92.2 -61.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -37.6 -146.5 -73.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -71.4 -120.8 -139.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -47.2 -90.4 -104.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -36.5 -64.3 -96.4 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -631.4 -2,328.8 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 0.3 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -72.7 -62.2 -71.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 9.4 2.6 7.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 9.4 2.6 7.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 76.4 48.4 72.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -283.6 -208.0 -516.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.8 0.8 0.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.2 0.6 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 10.9 34.7 21.1 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -316.6 -448.9 -1,106.8 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -48.3 -123.9 -80.2 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -33.3 -92.2 -61.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.6 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -37.6 -146.5 -73.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -37.6 -146.5 -73.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 457.7 459.6 1,076.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 457.7 459.6 1,076.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 15.1 17.6 15.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 442.5 442.0 1,060.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PIQ Shortsell

Frequently Asked Questions

The current share price of Proteomics International Laboratories Ltd. (PIQ:ASX) is AU$0.9.
The 52-week high share price for Proteomics International Laboratories Ltd. (PIQ:ASX) is AU$1.18.
The 52-week low share price for Proteomics International Laboratories Ltd. (PIQ:ASX)? is AU$0.61.
Proteomics International Laboratories Ltd. (PIQ:ASX) does not pay a dividend.
Proteomics International Laboratories Ltd. (PIQ:ASX) does not pay a dividend.
Proteomics International Laboratories Ltd. (PIQ:ASX) has a franking level of 0%.
Proteomics International Laboratories Ltd. (PIQ:ASX) is classified in the Healthcare.
The current P/E ratio for Proteomics International Laboratories Ltd. (PIQ:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.